Outcome Capital Announces Acquisition of Propella Therapeutics
Astellas Pharma has completed the acquisition of Propella Therapeutics that has become a wholly owned subsidiary of Astellas.
Propella Therapeutics Announces Presentation of Updated Phase 1/2a Data of PRL-02 for the Treatment of Advanced Prostate Cancer at 2023 ASCO Genitourinary (GU) Cancers Symposium
PITTSBORO, N.C., Sept. 08, 2022 (GLOBE NEWSWIRE) -- Propella Therapeutics, Inc. (“Propella” or “the Company”), a private, clinical-stage biopharmaceutical company developing best-in-class oncology therapeutics, today announced that Dr. Jose Avitia of the New Mexico Cancer Center will present data from the Company’s ongoing Phase 1/2 trial of PRL-02 for the treatment of advanced prostate cancer on Sunday, September 11 at 12:00 pm at the European Society for Medical Oncology (ESMO) Congress 2022. Details of the poster presentation are below:
Propella to Receive Upfront Payment, Regulatory and Sales Milestones, and Royalties Phase 2 Study of CGS-200-5 Reduced Pain by 50% in Patients with Moderate to Severe Osteoarthritis of the Knee ...
PITTSBORO, N.C., June 29, 2021 (GLOBE NEWSWIRE) -- Propella Therapeutics, Inc. (“Propella”), a private, clinical-stage biopharmaceutical company developing best-in-class oncology therapeutics, today announced the dosing of the first patient in the Phase 1/2a clinical trial studying its lead patented product candidate, PRL-02 (abiraterone decanoate), for the treatment of metastatic prostate cancer.
PITTSBORO, N.C., May 19, 2021 /PRNewswire/ -- Propella Therapeutics Inc. (Propella), a biopharmaceutical company focused on developing innovative, best-in-class oncology drugs, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for PRL-02 (abiraterone decanoate), a potentially best-in-class therapy for metastatic prostate cancer. Under the IND, Propella plans to initiate an open-label, phase 1/2a clinical study in June 2021. The phase 1 portion will have a dose-escalation design that will assess the safety, tolerability, pharmacokinetics, and preliminary clinical activity of PRL-02 in patients with metastatic prostate cancer.
PITTSBORO, N.C., Feb. 23, 2021 /PRNewswire/ -- Propella Therapeutics Inc. (Propella), a leader in the development of innovative, best-in-class prescription products, and the National Cancer Institute (NCI), part of the National Institutes of Health, have entered into a Cooperative Research and Development Agreement (CRADA). Under this new partnership, Propella and NCI will conduct a multi-center clinical trial to evaluate abiraterone decanoate, as a new therapy for metastatic prostate cancer.